| DC Field | Value | Language |
|---|
| dc.contributor.author | Stepenko, Yu. V. | - |
| dc.contributor.author | Shcheblykina, O. V. | - |
| dc.contributor.author | Peresypkina, A. A. | - |
| dc.contributor.author | Shmigerova, V. S. | - |
| dc.contributor.author | Yomna Y.O.M. Akhmed | - |
| dc.contributor.author | Danilenko, A. P. | - |
| dc.contributor.author | Lyapkalov, N. S. | - |
| dc.date.accessioned | 2025-11-17T11:44:59Z | - |
| dc.date.available | 2025-11-17T11:44:59Z | - |
| dc.date.issued | 2025 | - |
| dc.identifier.citation | Nonclassical cardiovascular effects of imidazoline receptor agonists / Stepenko Yu.V., O.V. Shcheblykina, A.A. Peresypkina [et al.] // Research Results in Pharmacology. - 2025. - Vol.11, №3.-P. 77-86. - Doi: 10.18413/rrpharmacology.11.640. - Refer.: p. 83-85. | ru |
| dc.identifier.uri | http://dspace.bsuedu.ru/handle/123456789/65895 | - |
| dc.description.abstract | In general, the totality of data available to date indicates a high expediency of including imidazoline receptors in the repertoire of pharmacological targets, the impact on which can affect not only soft, but also hard endpoints in the treatment of cardiovascular pathology | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | imidazoline receptor agonists | ru |
| dc.subject | cardiovascular continuum | ru |
| dc.subject | chronic heart failure | ru |
| dc.subject | atherosclerosis | ru |
| dc.title | Nonclassical cardiovascular effects of imidazoline receptor agonists | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 11, № 3
|
